128 related articles for article (PubMed ID: 36522120)
1. Effect of triamcinolone acetonide on retinal inflammation and angiogenesis induced by pericyte depletion in mouse.
Otsuka T; Masuda T; Takahashi Y; Suzuki A; Uemura A; Arakawa R; Okabe T; Naito A
J Pharmacol Sci; 2023 Jan; 151(1):28-36. PubMed ID: 36522120
[TBL] [Abstract][Full Text] [Related]
2. Triamcinolone Acetonide Suppresses Inflammation and Facilitates Vascular Barrier Function in Human Retinal Microvascular Endothelial Cells.
Imai S; Otsuka T; Naito A; Shimazawa M; Hara H
Curr Neurovasc Res; 2017; 14(3):232-241. PubMed ID: 28625129
[TBL] [Abstract][Full Text] [Related]
3. Effects of Switching from Anti-VEGF Treatment to Triamcinolone Acetonide in Eyes with Refractory Macular Edema Associated with Diabetic Retinopathy or Retinal Vein Occlusion.
Tatsumi T; Oshitari T; Baba T; Takatsuna Y; Yamamoto S
Biomed Res Int; 2020; 2020():4529850. PubMed ID: 33274211
[TBL] [Abstract][Full Text] [Related]
4. Early change of central macular thickness after intravitreous triamcinolone or bevacizumab in diabetic macular edema or retinal vein occlusion.
Sonoda Y; Arimura N; Shimura M; Sakamoto T
Retina; 2011 Feb; 31(2):290-7. PubMed ID: 21102366
[TBL] [Abstract][Full Text] [Related]
5. Involvement of Cytokines in the Pathogenesis of Diabetic Macular Edema.
Noma H; Yasuda K; Shimura M
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33810434
[TBL] [Abstract][Full Text] [Related]
6. Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone.
Brooks HL; Caballero S; Newell CK; Steinmetz RL; Watson D; Segal MS; Harrison JK; Scott EW; Grant MB
Arch Ophthalmol; 2004 Dec; 122(12):1801-7. PubMed ID: 15596583
[TBL] [Abstract][Full Text] [Related]
7. Trans-Tenon's retrobulbar triamcinolone acetonide infusion for refractory diabetic macular edema after vitrectomy.
Koga T; Mawatari Y; Inumaru J; Fukushima M; Tanihara H
Graefes Arch Clin Exp Ophthalmol; 2005 Dec; 243(12):1247-52. PubMed ID: 16021497
[TBL] [Abstract][Full Text] [Related]
8. Early effects of intravitreal triamcinolone acetonide on inflammation and proliferation in human choroidal neovascularization.
Tatar O; Adam A; Shinoda K; Kaiserling E; Boeyden V; Claes C; Eckardt C; Eckert T; Pertile G; Scharioth GB; Yoeruek E; Szurman P; Bartz-Schmidt KU; Grisanti S
Arch Ophthalmol; 2009 Mar; 127(3):275-81. PubMed ID: 19273790
[TBL] [Abstract][Full Text] [Related]
9. Response of Retinal Sensitivity to Intravitreal Anti-angiogenic Bevacizumab and Triamcinolone Acetonide for Patients with Diabetic Macular Edema over One Year.
Mylonas G; Schranz M; Scholda C; Karst S; Reiter G; Baumann L; Schmidt-Erfurth U; Kriechbaum K
Curr Eye Res; 2020 Sep; 45(9):1107-1113. PubMed ID: 31961224
[TBL] [Abstract][Full Text] [Related]
10. Diabetic Macular Edema at the time of Cataract Surgery trial: a prospective, randomized clinical trial of intravitreous bevacizumab versus triamcinolone in patients with diabetic macular oedema at the time of cataract surgery - preliminary 6 month results.
Lim LL; Morrison JL; Constantinou M; Rogers S; Sandhu SS; Wickremasinghe SS; Kawasaki R; Al-Qureshi S
Clin Exp Ophthalmol; 2016 May; 44(4):233-42. PubMed ID: 26871700
[TBL] [Abstract][Full Text] [Related]
11. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema.
Sohn HJ; Han DH; Kim IT; Oh IK; Kim KH; Lee DY; Nam DH
Am J Ophthalmol; 2011 Oct; 152(4):686-94. PubMed ID: 21782151
[TBL] [Abstract][Full Text] [Related]
12. Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration.
Becerra EM; Morescalchi F; Gandolfo F; Danzi P; Nascimbeni G; Arcidiacono B; Semeraro F
Curr Drug Targets; 2011 Feb; 12(2):149-72. PubMed ID: 20887246
[TBL] [Abstract][Full Text] [Related]
13. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema.
Shimura M; Nakazawa T; Yasuda K; Shiono T; Iida T; Sakamoto T; Nishida K
Am J Ophthalmol; 2008 May; 145(5):854-61. PubMed ID: 18328456
[TBL] [Abstract][Full Text] [Related]
14. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.
Arimura N; Otsuka H; Yamakiri K; Sonoda Y; Nakao S; Noda Y; Hashiguchi T; Maruyama I; Sakamoto T
Ophthalmology; 2009 May; 116(5):921-6. PubMed ID: 19410951
[TBL] [Abstract][Full Text] [Related]
15. Triamcinolone acetonide modulates TGF‑β2‑induced angiogenic and tissue‑remodeling effects in cultured human retinal pigment epithelial cells.
Hsiao CC; Chang YC; Hsiao YT; Chen PH; Hsieh MC; Wu WC; Kao YH
Mol Med Rep; 2021 Nov; 24(5):. PubMed ID: 34523693
[TBL] [Abstract][Full Text] [Related]
16. Intracellular delivery of dendrimer triamcinolone acetonide conjugates into microglial and human retinal pigment epithelial cells.
Kambhampati SP; Mishra MK; Mastorakos P; Oh Y; Lutty GA; Kannan RM
Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):239-49. PubMed ID: 25701805
[TBL] [Abstract][Full Text] [Related]
17. Triamcinolone acetonide inhibits IL-6- and VEGF-induced angiogenesis downstream of the IL-6 and VEGF receptors.
Ebrahem Q; Minamoto A; Hoppe G; Anand-Apte B; Sears JE
Invest Ophthalmol Vis Sci; 2006 Nov; 47(11):4935-41. PubMed ID: 17065510
[TBL] [Abstract][Full Text] [Related]
18. Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment.
Călugăru D; Călugăru M
Graefes Arch Clin Exp Ophthalmol; 2018 May; 256(5):1035-1037. PubMed ID: 29353345
[No Abstract] [Full Text] [Related]
19. Triamcinolone acetonide suppresses interleukin-1 beta-mediated increase in vascular endothelial growth factor expression in cultured rat Müller cells.
Itakura H; Akiyama H; Hagimura N; Doi H; Tanaka T; Kishi S; Kurabayashi M
Graefes Arch Clin Exp Ophthalmol; 2006 Feb; 244(2):226-31. PubMed ID: 16049703
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results.
Kriechbaum K; Prager S; Mylonas G; Scholda C; Rainer G; Funk M; Kundi M; Schmidt-Erfurth U;
Eye (Lond); 2014 Jan; 28(1):9-15; quiz 16. PubMed ID: 24336297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
